CompletedPhase 3NCT05254457
Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis
Studying Ledderhose disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Endo Pharmaceuticals
- Principal Investigator
- Nina GreenEndo Pharmaceuticals
- Intervention
- EN3835(biological)
- Enrollment
- 145 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (27)
- Endo Clinical Trial Site #12, Bakersfield, California, United States
- Endo Clinical Trial Site #3, Fresno, California, United States
- Endo Clinical Trial Site #23, La Mesa, California, United States
- Endo Clinical Trial Site #13, Tarzana, California, United States
- Endo Clinical Trial Site #15, Vista, California, United States
- Endo Clinical Trial Site #18, Whittier, California, United States
- Endo Clinical Trial Site #24, Miami, Florida, United States
- Endo Clinical Trial Site #8, Pinellas Park, Florida, United States
- Endo Clinical Trial Site #21, Sweetwater, Florida, United States
- Endo Clinical Trial Site #22, Lawrenceville, Georgia, United States
- Endo Clinical Trial Site #25, Meridian, Idaho, United States
- Endo Clinical Trial Site #19, Decatur, Illinois, United States
- Endo Clinical Trial Site #2, O'Fallon, Illinois, United States
- Endo Clinical Trial Site #14, Springfield, Illinois, United States
- Endo Clinical Trial Site #6, Pasadena, Maryland, United States
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05254457 on ClinicalTrials.govOther trials for Ledderhose disease
Additional recruiting or active studies for the same condition.